[Extracorporeal removal of pathogens using a biomimetic adsorber-A new treatment strategy for the intensive care unit : Seraph® 100 Microbind® Affinity Blood Filter and its fields of application].

IF 1.3 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Medizinische Klinik-Intensivmedizin Und Notfallmedizin Pub Date : 2024-07-10 DOI:10.1007/s00063-024-01153-9

Malin-Theres Seffer, Jan T Kielstein

{"title":"[Extracorporeal removal of pathogens using a biomimetic adsorber-A new treatment strategy for the intensive care unit : Seraph® 100 Microbind® Affinity Blood Filter and its fields of application].","authors":"Malin-Theres Seffer, Jan T Kielstein","doi":"10.1007/s00063-024-01153-9","DOIUrl":null,"url":null,"abstract":"Background: In 2019 the World Health Organization (WHO) listed antimicrobial resistance among the top 10 threats to global health. The Seraph® 100 Microbind® Affinity blood filter (Seraph® 100) has been in use since 2019 to eliminate pathogens from the bloodstream in addition to anti-infective pharmacotherapy. It is the first device used to rapidly and efficiently reduce the number of circulating bacteria and viruses.Objective: After a background on the concept of extracorporeal pathogen removal in general, this review summarizes the preclinical and clinical data on the Seraph® 100 Affinity Blood Filter. The clinical effect of this treatment and potential therapeutic options are described.Methods: Structured PubMed review including references published up to February 2024.Results: Case reports, uncontrolled observational studies and data from registries show widespread clinical use of the Seraph® 100 ranging from difficult to treat bacterial (super) infections to viral infections. The treatment can be done as stand-alone hemoperfusion or in combination with all forms of kidney replacement therapy as well as in extracorporeal membrane oxygenation.Conclusion: The use of the Seraph® 100 varies in terms of duration, concomitant therapy and clinical settings. Due to the absence of prospective controlled trials the clinical effect cannot be properly evaluated.","PeriodicalId":49019,"journal":{"name":"Medizinische Klinik-Intensivmedizin Und Notfallmedizin","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medizinische Klinik-Intensivmedizin Und Notfallmedizin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00063-024-01153-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In 2019 the World Health Organization (WHO) listed antimicrobial resistance among the top 10 threats to global health. The Seraph® 100 Microbind® Affinity blood filter (Seraph® 100) has been in use since 2019 to eliminate pathogens from the bloodstream in addition to anti-infective pharmacotherapy. It is the first device used to rapidly and efficiently reduce the number of circulating bacteria and viruses.

Objective: After a background on the concept of extracorporeal pathogen removal in general, this review summarizes the preclinical and clinical data on the Seraph® 100 Affinity Blood Filter. The clinical effect of this treatment and potential therapeutic options are described.

Methods: Structured PubMed review including references published up to February 2024.

Results: Case reports, uncontrolled observational studies and data from registries show widespread clinical use of the Seraph® 100 ranging from difficult to treat bacterial (super) infections to viral infections. The treatment can be done as stand-alone hemoperfusion or in combination with all forms of kidney replacement therapy as well as in extracorporeal membrane oxygenation.

Conclusion: The use of the Seraph® 100 varies in terms of duration, concomitant therapy and clinical settings. Due to the absence of prospective controlled trials the clinical effect cannot be properly evaluated.

查看原文本刊更多论文

[利用仿生吸附器体外清除病原体--重症监护室的新治疗策略：Seraph® 100 Microbind® 亲和血液过滤器及其应用领域]。

背景：2019年，世界卫生组织（WHO）将抗菌药耐药性列为全球健康的十大威胁之一。Seraph® 100 Microbind® 亲和血液过滤器（Seraph® 100）自 2019 年起开始使用，除抗感染药物治疗外，还可清除血液中的病原体。它是首个用于快速有效减少循环细菌和病毒数量的设备：在介绍了体外病原体清除概念的总体背景后，本综述总结了有关 Seraph® 100 亲和血液过滤器的临床前和临床数据。方法：方法：对截至 2024 年 2 月发表的参考文献进行结构化 PubMed 综述：病例报告、非对照观察研究和登记数据显示，Seraph® 100 血液过滤器在临床上得到广泛应用，包括难以治疗的细菌（超级）感染和病毒感染。这种治疗方法既可以单独进行血液灌流，也可以与各种形式的肾脏替代疗法以及体外膜氧合相结合：结论：Seraph® 100 的使用因持续时间、伴随治疗和临床环境而异。由于缺乏前瞻性对照试验，临床效果无法得到正确评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medizinische Klinik-Intensivmedizin Und Notfallmedizin MEDICINE, GENERAL & INTERNAL-

CiteScore

2.60

自引率

9.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Medizinische Klinik – Intensivmedizin und Notfallmedizin is an internationally respected interdisciplinary journal. It is intended for physicians, nurses, respiratory and physical therapists active in intensive care and accident/emergency units, but also for internists, anesthesiologists, surgeons, neurologists, and pediatricians with special interest in intensive care medicine. Comprehensive reviews describe the most recent advances in the field of internal medicine with special focus on intensive care problems. Freely submitted original articles present important studies in this discipline and promote scientific exchange, while articles in the category Photo essay feature interesting cases and aim at optimizing diagnostic and therapeutic strategies. In the rubric journal club well-respected experts comment on outstanding international publications. Review articles under the rubric "Continuing Medical Education" present verified results of scientific research and their integration into daily practice. The rubrics "Nursing practice" and "Physical therapy" round out the information.